Web14 apr. 2024 · Objective: To investigate the clinical characteristics and risk factors of ultra-high-risk (UHR) patients with newly diagnosed multiple myeloma (MM). Methods: We … Web14 apr. 2024 · Objective: To investigate the clinical characteristics and risk factors of ultra-high-risk (UHR) patients with newly diagnosed multiple myeloma (MM). Methods: We screened UHR patients with a survival of less than 24 months and we selected patients with a concurrent survival of more than 24 months as a control group. We retrospectively …
CAR T-cell Therapy vs. Bispecific Antibodies Int
WebThe International Staging System (ISS) looks at the results of 2 blood tests: beta-2 microglobulin (B2M) albumin level. If the level of B2M is raised or if the level of albumin is … Web22 mei 2024 · Despite the widespread use of highly active novel therapies, including proteasome inhibitors (PIs) and immunomodulators (IMiDs), overall survival (OS) in MM ranges from months to years. 1 In this setting, cytogenetic profiling has become a powerful means of risk stratifying MM patients at diagnosis, with modalities including conventional … dr. althea aurora cover cushion
A simple additive staging system for newly diagnosed multiple myeloma …
Web28 jul. 2024 · The recently introduced Revised International Staging System (R-ISS) for multiple myeloma (MM) integrates albumin, β2 microglobulin, lactate dehydrogenase (LDH) with high-risk cytogenetic aberrations (CA), i.e., t(4;14) and t(14;16) and del17p using fluorescent in situ hybridization (FISH). We evaluated utility of nucleic acid-based tests of … WebRevised International Staging System Is Predictive and Prognostic for Early Relapse ( <24 months) after Autologous Transplantation for Newly Diagnosed Multiple Myeloma Biol Blood Marrow Transplant. 2024 Apr;25 (4):683-688. doi: 10.1016/j.bbmt.2024.12.141. Epub 2024 Dec 21. Authors WebRevised International Staging System distribution According to the R-ISS, 86 (18%) patients were rated as R-ISS-1, 83 (18%) rated as R-ISS-3 and 306 (64%) were rated as R-ISS-2. The distribution within the R-ISS in the original IMWG cohort was 28% for R-ISS-1, 62% for R-ISS-2 and 10% for R-ISS-3. emory university health services